In clinical trials
Digestive & weight
Mazdutide
Evidence
Clinical trials
Class
Dual GLP-1 and glucagon receptor agonist
KEY TAKEAWAY
Mazdutide is a peptide that activates both the GLP-1 and glucagon receptors. Innovent Biologics developed it together with Eli Lilly. Mazdutide is not FDA-approved. It has been approved in China for weight management and is in clinical trials elsewhere.
Written by the Veylo editorial team · Updated
November 2026
What it is
Dual GLP-1 and glucagon receptor agonist
Being studied for
Studied for obesity, type 2 diabetes and fatty liver disease
Key fact
Mazdutide is not FDA-approved. It has been approved in China for weight management and is in clinical trials elsewhere.
Route
Weekly subcutaneous injection
Evidence strength
Clinical trials
Mazdutide is a peptide that activates both the GLP-1 and glucagon receptors. Innovent Biologics developed it together with Eli Lilly.
GLP-1 activity reduces appetite and improves blood sugar control. Glucagon activity may raise energy use and reduce fat in the liver.
Mazdutide is not FDA-approved. It has been approved in China for weight management and is in clinical trials elsewhere.
Studied for obesity, type 2 diabetes and fatty liver disease.
Nausea, vomiting and diarrhea were the most common effects in trials.
Mazdutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.